{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:54:59Z","timestamp":1740164099727,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2022M721987"],"award-info":[{"award-number":["2022M721987"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-70874-w","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T15:03:20Z","timestamp":1725375800000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimal management of breast cancer with physical exam negative\/radiological abnormal axilla"],"prefix":"10.1038","volume":"14","author":[{"given":"Zhao","family":"Bi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe-Dong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng-Fei","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"issue":"10","key":"70874_CR1","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S1470-2045(10)70207-2","volume":"11","author":"DN Krag","year":"2010","unstructured":"Krag, D. N. et al. Sentinel lymph node resection compared with conventional axillary lymph node dissection in clinically node-negative patients with breast cancer: Overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 11(10), 927\u2013933 (2010).","journal-title":"Lancet Oncol."},{"issue":"10","key":"70874_CR2","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano, A. E. et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (alliance) randomized clinical trial. JAMA 318(10), 918\u2013926 (2017).","journal-title":"JAMA"},{"issue":"12","key":"70874_CR3","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker, M. et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981\u201322023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 15(12), 1303\u20131310 (2014).","journal-title":"Lancet Oncol."},{"issue":"11","key":"70874_CR4","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1097\/JS9.0000000000000664","volume":"109","author":"Z Bi","year":"2023","unstructured":"Bi, Z., Ren, T. Y., Zhang, Z. P. & Wang, Y. S. The management concept of breast cancer with clinically node-negative\/imaging node-positive disease. Int. J. Surg. 109(11), 3727\u20133729 (2023).","journal-title":"Int. J. Surg."},{"key":"70874_CR5","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1200\/JCO.21.00934","volume":"39","author":"M Brackstone","year":"2021","unstructured":"Brackstone, M. et al. Management of the axilla in early-stage breast cancer: Ontario Health (Cancer Care Ontario) and ASCO guideline. J. Clin. Oncol. 39, 3056\u20133082 (2021).","journal-title":"J. Clin. Oncol."},{"key":"70874_CR6","doi-asserted-by":"publisher","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","volume":"20","author":"WJ Gradishar","year":"2022","unstructured":"Gradishar, W. J. et al. Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 20, 691\u2013722 (2022).","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"12","key":"70874_CR7","first-page":"12","volume":"33","author":"Society of Breast Cancer China Anti-Cancer Association, Breast Oncology Group of the Oncology Branch of the Chinese Medical Association","year":"2023","unstructured":"Society of Breast Cancer China Anti-Cancer Association, Breast Oncology Group of the Oncology Branch of the Chinese Medical Association. Guidelines for breast cancer diagnosis and treatment by China Anti-cancer Association (2024 Edition). China Oncol. 33(12), 12\u201392 (2023).","journal-title":"China Oncol."},{"issue":"2","key":"70874_CR8","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10549-020-05851-8","volume":"184","author":"Z Bi","year":"2020","unstructured":"Bi, Z. et al. Efficacy and safety analysis of paclitaxel, docetaxel and liposomal paclitaxel after neoadjuvant therapy in breast cancer. Breast Cancer Res. Treat. 184(2), 397\u2013405 (2020).","journal-title":"Breast Cancer Res. Treat."},{"issue":"96","key":"70874_CR9","volume":"2021","author":"Mathew G and Agha R, for the STROCSS Group. STROCSS","year":"2021","unstructured":"Mathew G and Agha R, for the STROCSS Group. STROCSS. Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery. Int. J. Surg. 2021(96), 106165 (2021).","journal-title":"Int. J. Surg."},{"issue":"4","key":"70874_CR10","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1245\/s10434-015-4944-y","volume":"23","author":"M Pilewskie","year":"2016","unstructured":"Pilewskie, M., Mautner, S. K., Stempel, M., Eaton, A. & Morrow, M. Does a positive axillary lymph node needle biopsy result predict the need for an axillary lymph node dissection in clinically node-negative breast cancer patients in the ACOSOG Z0011 era?. Ann. Surg. Oncol. 23(4), 1123\u20131128 (2016).","journal-title":"Ann. Surg. Oncol."},{"key":"70874_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.20892\/j.issn.2095-3941.2022.0625","volume":"20","author":"Z Bi","year":"2023","unstructured":"Bi, Z. et al. Optimization of regional nodal irradiation in the era of sentinel lymph node biopsy. Cancer Biol. Med. 20, 89\u201392 (2023).","journal-title":"Cancer Biol. Med."},{"doi-asserted-by":"crossref","unstructured":"Eleftherios, PM., Hanna, B., Julia, RW., et al. Loco-regional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant chemotherapy: Primary outcomes of NRG Oncology\/NSABP B-51\/RTOG 1304. SABCS meeting, 2023, GS02-07.","key":"70874_CR12","DOI":"10.1158\/1538-7445.SABCS23-GS02-07"},{"issue":"10","key":"70874_CR13","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S1470-2045(18)30380-2","volume":"19","author":"V Galimberti","year":"2018","unstructured":"Galimberti, V. et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micro-metastases (IBCSG 23\u201301): 10- year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol. 19(10), 1385\u20131393 (2018).","journal-title":"Lancet Oncol."},{"issue":"2","key":"70874_CR14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10549-022-06699-w","volume":"196","author":"V Man","year":"2022","unstructured":"Man, V., Luk, W. P., Fung, L. H. & Kwong, A. The role of pre-operative axillary ultrasound in assessment of axillary tumor burden in breast cancer patients: A systematic review and meta-analysis. Breast Cancer Res. Treat. 196(2), 245\u2013254 (2022).","journal-title":"Breast Cancer Res. Treat."},{"key":"70874_CR15","doi-asserted-by":"publisher","first-page":"779140","DOI":"10.3389\/fonc.2021.779140","volume":"11","author":"Z Bi","year":"2021","unstructured":"Bi, Z. et al. A three lncRNA set: AC009975.1, POTEH-AS1 and AL390243.1 as nodal efficacy biomarker of neoadjuvant therapy for HER-2 positive breast cancer. Front. Oncol. 11, 779140 (2021).","journal-title":"Front. Oncol."},{"issue":"2","key":"70874_CR16","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1245\/s10434-020-08928-2","volume":"28","author":"MF Almahariq","year":"2021","unstructured":"Almahariq, M. F. et al. Omission of axillary lymph node dissection is associated with inferior survival in breast cancer patients with residual N1 nodal disease following neoadjuvant chemotherapy. Ann. Surg. Oncol. 28(2), 930\u2013940 (2021).","journal-title":"Ann. Surg. Oncol."},{"issue":"13","key":"70874_CR17","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.20.03399","volume":"39","author":"LA Korde","year":"2021","unstructured":"Korde, L. A. et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO Guideline. J. Clin. Oncol. 39(13), 1485\u20131505 (2021).","journal-title":"J. Clin. Oncol."},{"doi-asserted-by":"crossref","unstructured":"Giacomo Montagna. The OPBC05\/EUBREAST-14R\/ICARO study, are nodal isolated tumor cells (ITCs) after neoadjuvant chemotherapy an indication for axillary dissection? SABCS meeting, 2023, GS02-07.","key":"70874_CR18","DOI":"10.1158\/1538-7445.SABCS23-GS02-02"},{"issue":"9935","key":"70874_CR19","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/S0140-6736(14)60488-8","volume":"383","author":"EBCTCG (Early Breast Cancer Trialists\u2019 Collaborative Group)","year":"2014","unstructured":"EBCTCG (Early Breast Cancer Trialists\u2019 Collaborative Group). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: Meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383(9935), 2127\u20132135 (2014).","journal-title":"Lancet"},{"issue":"23","key":"70874_CR20","first-page":"00835","volume":"S0923\u20137534","author":"G Curigliano","year":"2023","unstructured":"Curigliano, G. et al. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International consensus conference for the primary therapy of individuals with early breast cancer 2023. Ann. Oncol. S0923\u20137534(23), 00835\u201300839 (2023).","journal-title":"Ann. Oncol."},{"key":"70874_CR21","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/S1470-2045(20)30458-7","volume":"21","author":"I Smith","year":"2020","unstructured":"Smith, I. et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): An openlabel, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncol. 21, 1443\u20131454 (2020).","journal-title":"Lancet Oncol."},{"issue":"11","key":"70874_CR22","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1001\/jamaoncol.2016.1897","volume":"2","author":"LM Spring","year":"2016","unstructured":"Spring, L. M. et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: A systematic review and meta-analysis. JAMA Oncol. 2(11), 1477\u20131486 (2016).","journal-title":"JAMA Oncol."},{"issue":"8","key":"70874_CR23","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/jamaoncol.2022.1488","volume":"8","author":"M Martin","year":"2022","unstructured":"Martin, M. et al. Treatment with adjuvant abemaciclib plus endocrine therapy in patients with high-risk early breast cancer who received neoadjuvant chemotherapy: A prespecified analysis of the monarchE randomized clinical trial. JAMA Oncol. 8(8), 1190\u20131194 (2022).","journal-title":"JAMA Oncol."},{"issue":"4","key":"70874_CR24","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S1470-2045(21)00007-3","volume":"22","author":"M Piccart","year":"2021","unstructured":"Piccart, M. et al. 70-gene signature as an aid for treatment decisions in early breast cancer: Updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol. 22(4), 476\u2013488 (2021).","journal-title":"Lancet Oncol."},{"issue":"29","key":"70874_CR25","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1200\/JCO.22.00173","volume":"40","author":"EA Mittendorf","year":"2022","unstructured":"Mittendorf, E. A., King, T. A. & Tolaney, S. M. Impact of RxPONDER and monarchE on the surgical management of the axilla in patients with breast cancer. J. Clin. Oncol. 40(29), 3361\u20133364 (2022).","journal-title":"J. Clin. Oncol."},{"key":"70874_CR26","first-page":"2104","volume":"7534","author":"HJ Burstein","year":"2021","unstructured":"Burstein, H. J. et al. Customizing local and systemic therapies for women with early breast cancer: The St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann. Oncol. 7534, 2104\u20132119 (2021).","journal-title":"Ann. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70874-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70874-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70874-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T15:14:31Z","timestamp":1725376471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70874-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["70874"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-70874-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2024,9,3]]},"assertion":[{"value":"23 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20504"}}